1. subjects who require hospitalization. 2. patient has severe chronic obstructive or restrictive pulmonary disease (copd) as defined by prior pulmonary function tests, chronic renal failure, or significant liver abnormality (e.g., cirrhosis, transplant, etc.). 3. history of chronic fatigue syndrome prior to covid-19 infection. 4. patient is on chronic immunosuppressive medication. 5. patient requires surgery that could be life-threatening within the study window. 6. a history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or ingredients in 5% human albumin (n-acetyl tryptophan, sodium caprylate). 7. patient has known pregnancy or is currently breastfeeding. 8. participation in a trial such that enrollment in this study would fall within the time frame of the half-life of the other investigational product(s). 9. clinically significant findings via electrocardiogram (ecg), including acute myocardial infarction, acute ischemic changes, atrial fibrillation, atrial flutter, paced rhythms in individuals who have undergone permanent pacemaker placement, evidence of prior infarction, unchanged stable conduction abnormalities e.g., right bundle branch block, or any other finding which does not significantly impact mortality. 10. pre-existing co-morbid condition(s) preventing outcome assessments, e.g. disease or condition that would prevent ability to transfer and walk for 6 minutes, prior to confirmed covid-19 diagnosis (assisted walking devices are acceptable) 11. as a result of the medical review and screening investigation, the principal investigator considers the patient unfit for the study.

1. subjects who require hospitalization. 2. patient has severe chronic obstructive or restrictive pulmonary disease (copd) as defined by prior pulmonary function tests, chronic renal failure, or significant liver abnormality (e.g., cirrhosis, transplant, etc.). 3. history of chronic fatigue syndrome prior to covid-19 infection. 4. patient is on chronic immunosuppressive medication. 5. patient requires surgery that could be life-threatening within the study window. 6. a history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or ingredients in 5% human albumin (n-acetyl tryptophan, sodium caprylate). 7. patient has known pregnancy or is currently breastfeeding. 8. participation in a trial such that enrollment in this study would fall within the time frame of the half-life of the other investigational product(s). 9. clinically significant findings via electrocardiogram (ecg), including acute myocardial infarction, acute ischemic changes, atrial fibrillation, atrial flutter, paced rhythms in individuals who have undergone permanent pacemaker placement, evidence of prior infarction, unchanged stable conduction abnormalities e.g., right bundle branch block, or any other finding which does not significantly impact mortality. 10. pre-existing co-morbid condition(s) preventing outcome assessments, e.g. disease or condition that would prevent ability to transfer and walk for 6 minutes, prior to confirmed covid-19 diagnosis (assisted walking devices are acceptable) 11. as a result of the medical review and screening investigation, the principal investigator considers the patient unfit for the study.

subjects who require hospitalization. patient has severe chronic obstructive or restrictive pulmonary disease (copd) as defined by prior pulmonary function tests, chronic renal failure, or significant liver abnormality (e.g., cirrhosis, transplant, etc.). history of chronic fatigue syndrome prior to covid-19 infection. patient is on chronic immunosuppressive medication. patient requires surgery that could be life-threatening within the study window. a history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or ingredients in 5% human albumin (n-acetyl tryptophan, sodium caprylate). patient has known pregnancy or is currently breastfeeding. participation in a trial such that enrollment in this study would fall within the time frame of the half-life of the other investigational product(s). clinically significant findings via electrocardiogram (ecg), including acute myocardial infarction, acute ischemic changes, atrial fibrillation, atrial flutter, paced rhythms in individuals who have undergone permanent pacemaker placement, evidence of prior infarction, unchanged stable conduction abnormalities e.g., right bundle branch block, or any other finding which does not significantly impact mortality. pre-existing co-morbid condition(s) preventing outcome assessments, e.g. disease or condition that would prevent ability to transfer and walk for 6 minutes, prior to confirmed covid-19 diagnosis (assisted walking devices are acceptable) as a result of the medical review and screening investigation, the principal investigator considers the patient unfit for the study.

subjects who require hospitalization. patient has severe chronic obstructive or restrictive pulmonary disease (copd) as defined by prior pulmonary function tests, chronic renal failure, or significant liver abnormality (e.g., cirrhosis, transplant, etc.). history of chronic fatigue syndrome prior to covid-19 infection. patient is on chronic immunosuppressive medication. patient requires surgery that could be life-threatening within the study window. a history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or ingredients in 5% human albumin (n-acetyl tryptophan, sodium caprylate). patient has known pregnancy or is currently breastfeeding. participation in a trial such that enrollment in this study would fall within the time frame of the half-life of the other investigational product(s). clinically significant findings via electrocardiogram (ecg), including acute myocardial infarction, acute ischemic changes, atrial fibrillation, atrial flutter, paced rhythms in individuals who have undergone permanent pacemaker placement, evidence of prior infarction, unchanged stable conduction abnormalities e.g., right bundle branch block, or any other finding which does not significantly impact mortality. pre-existing co-morbid condition(s) preventing outcome assessments, e.g. disease or condition that would prevent ability to transfer and walk for 6 minutes, prior to confirmed covid-19 diagnosis (assisted walking devices are acceptable) as a result of the medical review and screening investigation, the principal investigator considers the patient unfit for the study.

1. subjects who require hospitalization. 2. patient has severe chronic obstructive or restrictive pulmonary disease (copd) as defined by prior pulmonary function tests, chronic renal failure, or significant liver abnormality (e.g., cirrhosis, transplant, etc.). 3. history of chronic fatigue syndrome prior to covid-19 infection. 4. patient is on chronic immunosuppressive medication. 5. patient requires surgery that could be life-threatening within the study window. 6. a history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or ingredients in 5% human albumin (n-acetyl tryptophan, sodium caprylate). 7. patient has known pregnancy or is currently breastfeeding. 8. participation in a trial such that enrollment in this study would fall within the time frame of the half-life of the other investigational product(s). 9. clinically significant findings via electrocardiogram (ecg), including acute myocardial infarction, acute ischemic changes, atrial fibrillation, atrial flutter, paced rhythms in individuals who have undergone permanent pacemaker placement, evidence of prior infarction, unchanged stable conduction abnormalities e.g., right bundle branch block, or any other finding which does not significantly impact mortality. 10. pre-existing co-morbid condition(s) preventing outcome assessments, e.g. disease or condition that would prevent ability to transfer and walk for 6 minutes, prior to confirmed covid-19 diagnosis (assisted walking devices are acceptable) 11. as a result of the medical review and screening investigation, the principal investigator considers the patient unfit for the study.

1. subjects who require hospitalization. 2. patient has severe chronic obstructive or restrictive pulmonary disease (copd) as defined by prior pulmonary function tests, chronic renal failure, or significant liver abnormality (e.g., cirrhosis, transplant, etc.). 3. history of chronic fatigue syndrome prior to covid-19 infection. 4. patient is on chronic immunosuppressive medication. 5. patient requires surgery that could be life-threatening within the study window. 6. a history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or ingredients in 5% human albumin (n-acetyl tryptophan, sodium caprylate). 7. patient has known pregnancy or is currently breastfeeding. 8. participation in a trial such that enrollment in this study would fall within the time frame of the half-life of the other investigational product(s). 9. clinically significant findings via electrocardiogram (ecg), including acute myocardial infarction, acute ischemic changes, atrial fibrillation, atrial flutter, paced rhythms in individuals who have undergone permanent pacemaker placement, evidence of prior infarction, unchanged stable conduction abnormalities e.g., right bundle branch block, or any other finding which does not significantly impact mortality. 10. pre-existing co-morbid condition(s) preventing outcome assessments, e.g. disease or condition that would prevent ability to transfer and walk for 6 minutes, prior to confirmed covid-19 diagnosis (assisted walking devices are acceptable) 11. as a result of the medical review and screening investigation, the principal investigator considers the patient unfit for the study.